leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics ends fiscal 2Q with C$22.4M in cash ahead of Phase III trial of lead drug otenaproxesul

Otenaproxesul, or ATB-346, is a non-addictive medication for chronic pain and inflammation

Antibe Therapeutics Inc -
The upcoming Phase III study will replicate the Phase IIB gastrointestinal safety and dose-ranging efficacy studies with larger sample sizes and longer treatment durations

Antibe Therapeutics Inc (TSE:ATE) (OTCQB:ATBPF) (FRA:4B7) ended its fiscal 2Q with C$22.4 million in the bank as it prepares to launch Phase III trials of its lead drug candidate otenaproxesul, a non-addictive medication for chronic pain and inflammation. 

The Canadian pharmaceutical firm revealed secondary data from Phase IIB trials of otenaproxesul in June confirmed the drug’s potency to treat osteoarthritis pain.  

During the quarter ended September 30, Antibe also completed third-party studies for seven of its largest markets, showing “impressive” commercial opportunity for otenaproxesul, according to the company.

READ: Antibe Therapeutics plans to file IND with regulator for lead drug otenaproxesul

The upcoming Phase III study will replicate the Phase IIB gastrointestinal safety and dose-ranging efficacy studies with larger sample sizes and longer treatment durations, according to Antibe. Registration is slated to being in spring 2021 with subsequent follow-up trials staggered every several months thereafter. Initially, trials will focus on the US, but Antibe is looking to do global trials for Europe and key Asian markets.

The firm reported revenue of nearly C$2.9 million compared to the $2.2 million from the year-ago quarter, according to its financials. Its net loss came in at C$8.9 million compared C$4.9 million in 2Q 2019 as is common with pharmaceutical firms at this stage of the product life cycle.

“We’ve made tremendous progress this quarter in preparing our lead drug for Phase III trials and partnering,” Dan Legault, Antibe’s CEO said in a statement Friday.

“We are getting closer to the start of our Phase III program, with a total of eight Phase III-enabling studies now running in parallel. Additionally, the recent commercial data strengthens our position as we engage partners for the large markets. Finally, we are executing our capital markets strategy to increase institutional awareness and liquidity, highlighted by the recent graduation to the TSX.”

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Antibe Therapeutics Inc

Price: 4.01 CAD

TSX:ATE
Market: TSX
Market Cap: $155.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read